OncoSec Medical Inc - ESG Rating & Company Profile powered by AI
If you work at OncoSec Medical Inc and you would like to use your ESG aseessment, please contact us. Alternative corporations in the rating peer group for OncoSec Medical Inc are displayed. The assessment of OncoSec Medical Inc is assembled by All Street Sevva using leading AI.
OncoSec Medical Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 4.0, social score of 6.7 and governance score of 4.6.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Novartis AG | 9.2 | High |
2 | Daiichi Sankyo Co Ltd | 8.9 | High |
912 | Vivanza Biosciences Ltd | 5.3 | High |
912 | ValiRx PLC | 5.3 | High |
958 | OncoSec Medical Inc | 5.2 | High |
958 | Altimmune Inc | 5.2 | High |
958 | Agios Pharmaceuticals Inc | 5.2 | High |
... | ... | ... | |
2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
2749 | Zyden Gentec Ltd | 0.0 | Low |
... | ... | ... |
Frequently Asked Questions
Does OncoSec Medical Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes OncoSec Medical Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes OncoSec Medical Inc report the average age of the workforce?
Sign up for free to unlockDoes OncoSec Medical Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes OncoSec Medical Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes OncoSec Medical Inc disclose cybersecurity risks?
Sign up for free to unlockDoes OncoSec Medical Inc offer flexible work?
Sign up for free to unlockDoes OncoSec Medical Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes OncoSec Medical Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes OncoSec Medical Inc conduct supply chain audits?
Sign up for free to unlockDoes OncoSec Medical Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes OncoSec Medical Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes OncoSec Medical Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes OncoSec Medical Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes OncoSec Medical Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes OncoSec Medical Inc disclose water use targets?
Sign up for free to unlockDoes OncoSec Medical Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid OncoSec Medical Inc have a product recall in the last two years?
Sign up for free to unlockDoes OncoSec Medical Inc disclose incidents of discrimination?
Sign up for free to unlockDoes OncoSec Medical Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas OncoSec Medical Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes OncoSec Medical Inc disclose parental leave metrics?
Sign up for free to unlockDoes OncoSec Medical Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes OncoSec Medical Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes OncoSec Medical Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes OncoSec Medical Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes OncoSec Medical Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes OncoSec Medical Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs OncoSec Medical Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes OncoSec Medical Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes OncoSec Medical Inc disclose its waste policy?
Sign up for free to unlockDoes OncoSec Medical Inc report according to TCFD requirements?
Sign up for free to unlockDoes OncoSec Medical Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes OncoSec Medical Inc disclose energy use targets?
Sign up for free to unlockDoes OncoSec Medical Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes OncoSec Medical Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for OncoSec Medical Inc
These potential risks are based on the size, segment and geographies of the company.
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.